Actinium pharmaceuticals, inc. (ATNM)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11
Cash Flows from Operating Activities:
Net loss

-21,899

-23,616

-23,165

-23,001

-23,653

-22,497

-22,672

-24,862

-26,601

-28,133

-28,409

-27,980

-24,321

-24,166

-21,514

-22,353

-21,025

-19,910

-22,041

-11,062

-24,687

-25,141

-20,485

-26,784

-10,773

-7,771

-9,362

-8,141

-8,361

-5,487

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

1,294

1,370

1,385

1,535

1,798

2,051

2,327

3,043

3,493

4,074

4,407

4,343

4,297

3,831

3,949

5,138

7,061

7,366

8,313

7,437

6,280

0

0

0

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

420

328

235

142

50

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,118

2,223

0

0

0

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

61

-

0

0

0

-

-

-

-

1

0

0

0

0

0

0

0

-

Loss on disposition of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

0

0

0

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

55

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Loss on disposition of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

324

553

775

0

0

0

-

Amortization of deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

106

179

252

0

0

0

-

Gain on extinguishment of liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

Gain on change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

304

396

527

673

2,530

779

970

617

3,812

6,880

7,153

15,151

-2,206

-8,048

-8,827

-18,074

-4,179

1,189

705

1,610

685

0

0

0

-

Changes in operating assets and liabilities:
Decrease in:
R&D reimbursable receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Prepaid expenses and other current assets

-253

-398

-510

-765

-100

-361

-439

-243

-1,397

-885

86

94

1,032

1,135

399

37

-162

-836

-672

-321

193

495

402

292

-106

-81

-75

56

18

0

0

0

-

Increase (decrease) in:
Accounts payable and accrued expenses

-1,255

980

-593

19

1,133

622

1,611

451

405

879

2,225

2,915

2,720

1,682

368

604

-793

-856

-48

618

1,874

1,419

251

155

-518

-424

494

60

334

0

0

0

-

Operating lease liabilities

-274

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses-related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-189

-239

-164

118

133

-97

158

158

50

373

31

31

31

0

0

0

-

Increase in Legal fees payable (Statement Of Cash Flows)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Increase in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Increase in accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Rounding error (Statement Of Cash Flows)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash Used In Operating Activities

-21,461

-20,737

-21,753

-20,601

-20,571

-19,452

-18,708

-21,637

-21,553

-22,625

-22,325

-21,407

-20,789

-20,512

-18,441

-17,487

-18,543

-19,626

-20,366

-17,670

-14,348

-10,645

-8,026

-6,471

-6,292

-6,365

-6,678

-6,577

-5,212

-3,799

0

0

0

Cash Flows from Investing Activities:
Payment of security deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

49

49

49

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment made for patent rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Purchase of property and equipment

63

70

128

140

96

86

34

23

24

40

35

40

59

63

88

75

47

27

24

149

151

159

143

17

16

8

2

2

2

0

0

0

-

Decrease of restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets transferred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash Used In Investing Activities

-63

-70

-128

-140

-96

-86

-34

-23

-24

-40

-35

-40

-109

-113

-138

-125

-47

-62

-58

-184

-186

-159

-143

-17

-16

-8

-2

-2

-2

-1

0

0

0

Cash Flows from Financing Activities:
Payments on note payable

249

0

0

0

-

-

-

-

-

-

-

-

265

265

268

277

283

287

250

192

161

157

139

138

140

140

103

65

0

0

0

0

-

Payments on finance leases

72

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales of shares of common stock and warrants, net of offering costs

-

-

-

-

16,976

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of common stock, net of offering costs

-

-

-

0

-

-

-

-

18,814

28,037

13,789

16,454

16,022

11,585

13,220

20,638

37,637

32,825

31,581

31,048

15,435

0

0

0

-

-

-

-

-

-

-

-

0

Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Proceeds from exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of warrants

1,503

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

159

0

0

0

-

-

-

0

-

-

-

-

-

Borrowings on convertible debt, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Sales of stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,469

4,469

5,129

0

0

0

-

Related party notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash Provided By Financing Activities

17,114

20,323

19,977

3,903

16,981

13,843

28,801

31,767

18,814

28,037

13,718

16,294

15,775

11,391

13,083

20,534

37,528

32,700

31,707

31,262

15,708

18,565

17,191

9,126

6,223

7,797

7,830

4,404

5,129

664

0

0

0

Net change in cash, cash equivalents and restricted cash

-4,411

-484

-1,904

-16,838

-3,686

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,234

-5,496

2,922

18,936

13,011

11,281

13,407

1,173

7,760

9,020

2,637

-85

1,423

1,149

-2,174

-85

-3,137

0

0

0

Supplemental disclosures of cash flow information:
Cash paid for interest

26

0

0

0

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4

-

8

8

6

0

0

0

0

0

0

0

0

0

0

0

0

-

Cash paid for taxes

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

Supplemental disclosure of non-cash investing and financing activities:
Stock issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Subscription receivable received subsequent to balance sheet date

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued with stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,738

4,738

4,738

4,738

0

0

0

0

-

-

-

-

-

-

-

-

-

Transfer from derivative liability classification to equity classification

-

-

-

-

-

-

-

-

-

-

-

-

-

17

17

17

48

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Beneficial conversion feature discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Insurance financed through premium finance agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Transfer warrant derivatives from liability to equity classification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Transfer warrant derivatives from liability to equity classification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,231

0

0

0

-

Fair value of warrants issued with debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Fair value of warrants issued with stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,075

3,393

0

0

0

-

Fair value of warrants issued to the placement agent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

499

658

0

0

0

-

Conversion of notes payable and accrued interest to stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,571

981

981

0

0

0

-